Factor VIII Deficiency and Hemophilia A: Understanding High and Low Factor Activity Levels

Introduction

Hemophilia A is a rare X-linked recessive bleeding disorder resulting from mutations in the F8 gene, which encodes coagulation Factor VIII (FVIII). This deficiency disrupts the intrinsic pathway of the coagulation cascade, leading to a lifelong tendency to bleed.¹ With an incidence of approximately 1 in 5,000 male births, its clinical severity is closely correlated with residual FVIII activity.² Notably, approximately 30% of males with hemophilia A have no family history of the disorder, meaning a negative family history does not exclude the diagnosis.³ Hemophilia primarily affects males who inherit an affected X chromosome from their mother. Females with hemophilia are rare.¹ The therapeutic landscape for Hemophilia A has evolved from episodic bleed management to a prophylactic standard of care, supported by advances in treatment options that aim to provide more consistent bleed protection.

Factor VIII in Hemostasis: A Key Player

Factor VIII circulates as a heterodimer non-covalently bound to its chaperone, von Willebrand factor (VWF), which protects it from premature proteolytic degradation and extends its plasma half-life from approximately 2 hours to a clinically relevant 8-12 hours.^1,4 This codependence is evident in Type 2N von Willebrand disease, where specific VWF mutations prevent FVIII binding, leading to rapid FVIII clearance and a clinical phenotype resembling mild or moderate Hemophilia A.⁵

 

The sequence of events can be summarized as follows^2,6:

Diagnosis and Severity Classification of Hemophilia A

The diagnosis of hemophilia A involves a combination of clinical assessment and laboratory testing. Clinically, patients often present with a history of prolonged bleeding, spontaneous joint or muscle hemorrhages, and a positive family history. Laboratory evaluation typically reveals a prolonged activated partial thromboplastin time (aPTT) with normal prothrombin time (PT) and platelet count.¹ Definitive diagnosis requires a quantitative FVIII activity assay, with concurrent normal VWF antigen and activity levels to exclude von Willebrand disease.³

FVIII activity is quantified via two primary methods: the one-stage clotting assay and the chromogenic substrate assay.

• The one-stage assay is a clot-based aPTT test that measures the time to fibrin clot formation after the addition of reagents to patient plasma. It is widely available but prone to pre-analytical variability and may yield discordant results with certain FVIII variants and therapies.⁷
• The chromogenic assay, which quantifies FVIIIa cofactor activity in FX to FXa conversion, is more precise but less accessible and expensive. Assay discrepancies are clinically significant, especially when monitoring extended half-life products (e.g., PEGylated FVIII), underscoring the need for close laboratory collaboration to ensure appropriate assay selection.⁸

The severity of Hemophilia A is determined by FVIII activity, guiding prognosis and therapeutic strategy. The normal range for FVIII activity is 50 to 150 IU/dL (or %).¹

Genetic testing of the F8 gene is now standard in hemophilia care. It confirms the diagnosis, enables carrier detection and prenatal counseling, and helps predict inhibitor risk.³

Clinical Consequences and Complications of Hemophilia A

Hemophilic arthropathy is the leading cause of morbidity in severe Hemophilia A. Recurrent hemarthroses, particularly in target joints like the knees, ankles, and elbows, trigger a cascade of synovial inflammation, cartilage destruction, and subchondral bone damage, leading to chronic pain, deformity, and profound disability.^1,2

The most challenging complication is the development of neutralizing alloantibodies, known as inhibitors, against exogenous FVIII. These render FVIII replacement therapy ineffective and occur in 20 to 30% of patients with severe hemophilia A, typically within the first 50 exposure days.^3,9 Management of inhibitor development requires specialized therapies, such as immune tolerance induction or bypassing agents, and significantly increases the cost and complexity of care. Historically, bloodborne viral infections (HIV, HBV, HCV) were a major complication of plasma-derived products, but this risk has been virtually eliminated in developed countries due to modern viral screening, inactivation techniques, and the widespread use of recombinant products.⁹

Advances in Hemophilia A Treatment: Expanding the Therapeutic Landscape

Hemophilia A management has shifted from on-demand treatment to prophylaxis, aiming to convert a severe phenotype into a milder one by maintaining a minimum FVIII trough level.

1. FVIII Replacement: EHL
   Prophylaxis with standard half-life FVIII products requires frequent infusions (3-4 times weekly), posing a significant burden. Extended half-life (EHL) products are designed to prolong FVIII survival compared to standard half-life products,⁸ allowing for extended activity levels and dosing intervals.⁴
2. Non-Factor Therapies
   These subcutaneous agents help rebalance hemostasis without replacing FVIII, representing a breakthrough for patients, especially those with inhibitors.

      3. Management of Inhibitors 
          Acute bleeds in patients with inhibitors are managed with bypassing agents like activated prothrombin complex concentrate (aPCC) or recombinant activated FVII (rFVIIa).^3,9

Conclusion

Hemophilia A management has shifted from treating bleeds to preventing them, with the goal of maintaining FVIII levels that support normal activity and joint health. Advances include extended half-life FVIII products, subcutaneous non-factor therapies, and gene therapy, offering potential functional cure. Each option requires understanding of mechanism, monitoring, and risks associated with the treatment. Multidisciplinary care remains essential, but innovative treatment options are transforming outcomes and quality of life.